Hearing aids improve cognition in human trials across independent labs, but other trials show no clear cognitive effect. Human cohorts link use with lower dementia risk, whereas a trial in people with mild cognitive impairment and moderate-to-severe hearing loss shows no clear dementia effect. Some papers declare company ties.
97 findings in 58 papers from 2017 to 2026, 12 of them since April 2026
Independent labs found the same change in people. 37 independent labs in 16 countries.
“The 3-year change in these proportions did not differ between the hearing intervention arm and the health education control participants.”
Humans: replicated by independent labs. Cells, worms or flies and mice: nothing yet.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
28 peopleBothmean age=77.4 yearsOlder adults; early compared to late hearing aid intervention
AAIC 2025 abstract, Dec 25, 2025
What did studies of hearing aids find?
46
Studies of hearing aids measured 46 outcomes; the most studied are cognitive function (10 studies), cognitive decline (7) and dementia (3).
Cognitive function
↑upin humans9↔no changein humans2RR 5.94
10 studies
Hearing aids improve cognitive function in humans (RR, 5.94; 95% CI, 2.46-14.37).
“The rate of cognitive improvement (CDR = 0) was 15.34% (95% CI, 11.84%-19.62%) in the intervention group and 2.36% (95% CI, 0.99%-5.22%) in the control group (RD, 12.00%; 95% CI, 8.79%-15.21%; RR, 5.94; 95% CI, 2.46-14.37).”
Hearing aids improve cognitive function in humans.
“After six months of hearing aid use, we re-evaluated the MMSE and SRT scores and serum biomarkers levels in the ARHL group: we recorded significant improvements both in cognitive and word recognition tests and in biomarker values.”
Hearing aids showed no clear effect on cognitive function in older adults with hearing loss (Difference 0·002 [95% CI: −0·077, 0·081]).
“In the analysis of the primary outcome of 3-year global cognitive change combining both the ARIC and de novo cohorts, global cognitive change (in SD units) was not significantly different between HI and SA control ( and; Difference 0·002 [95% CI: −0·077, 0·081], p=0·96).”
Human trialin older adults with hearing loss3-yearn = 977
Hearing aids showed no clear effect on cognitive function in humans (untreated hearing loss without substantial cognitive impairment) (difference 0·002 [-0·077 to 0·081]; p=0·96).
“In the primary analysis combining the ARIC and de novo cohorts, 3-year cognitive change (in SD units) was not significantly different between the hearing intervention and health education control groups”
Human trialuntreated hearing loss without substantial cognitive impairmentaudiological counselling and provision of hearing aids3 yearsn = 977
Hearing aids improve cognitive function in humans (active +14.9 vs. sham +5.7, ES=0.62).
“Hearing aid treatment as opposed to sham was associated with a significant improvement on RBANS Immediate Memory (active +14.9 vs. sham +5.7, ES=0.62, t=2.28, df=16, p=0.037).”
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry·
Hearing aids improve cognitive function in humans (comorbid MDD and moderate-profound hearing loss) (active +14.9 versus sham +5.7, t = 2.28, df = 16, p = 0.037).
“and immediate memory (active +14.9 versus sham +5.7, t = 2.28, df = 16, p = 0.037)”
Human trialcomorbid MDD and moderate-profound hearing loss12 weeks
Hearing aids are linked with better cognitive function in humans (age-related hearing loss) (MoCA 24.49 ± 2.78 vs. 21.00 ± 3.63, MMSE 25.81 ± 2.45 vs. 23.33 ± 3.33).
“The HA + group had significantly better MoCA (24.49 ± 2.78 vs. 21.00 ± 3.63; Z = -4.881, p < 0.001) and MMSE (25.81 ± 2.45 vs. 23.33 ± 3.33; Z = -4.118, p < 0.001) scores than the HA- group”
Hearing aids decrease cognitive decline in participants in the top quartile of predicted risk of cognitive decline (61.6% reduction (95% CI: 33.7%–94.1%)).
“More precisely, covariate‐adjusted estimates indicated that the three‐way interaction between predicted risk, time, and treatment assignment was equivalent to a 61.6% (95% CI: 33.7%–94.1%) reduction in cognitive decline.”
Human trialin participants in the top quartile of predicted risk of cognitive declinemedian follow-up time was 3.1 years (3.0, 3.2)
Alzheimer's & dementia : the journal of the Alzheimer's Association·
Hearing aids decrease cognitive decline in humans (top quartile of predicted risk of cognitive decline) (61.6% slower (95% CI: 33.7%-94.1%)).
“Among ACHIEVE participants in the top quartile of predicted risk, 3-year cognitive decline in the hearing intervention was 61.6% (95% confidence interval [CI]: 33.7%-94.1%) slower than the control.”
Human trialtop quartile of predicted risk of cognitive decline3-yearn = 977
Alzheimer's & dementia : the journal of the Alzheimer's Association·
Hearing aids decrease cognitive decline in the ARIC cohort (-48%, Difference 0·191 [95% CI: 0·022, 0·360]).
“In the ARIC cohort, HI was associated with a 48% reduction in 3-year cognitive change compared to SA control (Difference 0·191 [95% CI: 0·022, 0·360], p=0·027).”
Hearing aids are linked with lower cognitive decline in humans (moderate hearing impairment) (HR 0.16 (0.04-0.64)).
“A 2-year follow-up of participants with moderate hearing impairment yielded hazard ratios for MMSE score decrease of 0.30 (0.11-0.82) after 1 year and 0.16 (0.04-0.64) after 2 years in HA users.”
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology·
Hearing aids are linked with lower cognitive decline in humans (β=-0.02 after vs β=-0.1 before, p<.001).
“Decline in episodic memory scores was slower after (β=-0.02, p<.001) than before using hearing aids (β=-0.1, p<.001).”
Hearing aids decrease cognitive decline in participants most at risk for cognitive decline.
“The participants most at risk for cognitive decline, with lower education, lower income, more likely to identify as Black, and have more cardiovascular risk factors, were the participants who benefited most from the hearing intervention”
Reviewin participants most at risk for cognitive decline3 years
Hearing aids showed no clear effect on dementia in humans (RR, 0.59; 95% CI, 0.25-1.38).
“As the primary outcome, the 24-month incidence of conversion from MCI to dementia-level impairment did not differ significantly between the intervention group (3.09%; 95% CI, 1.62%-5.74%) and the control group (4.74%; 95% CI, 2.60%-8.29%; RD, −2.07%, 95% CI, −4.74% to 0.61%; RR, 0.59; 95% CI, 0.25-1.38; P =.23”
Hearing aids showed no clear effect on dementia in humans (mild cognitive impairment and moderate to severe hearing loss) (RR 0.59 (95% CI, 0.25-1.38)).
“No significant difference was observed in the primary outcome, in which the conversion rate from MCI to dementia-level impairment was 3.09% (95% CI, 1.62%-5.74%) in the intervention group vs 4.74%”
Human trialmild cognitive impairment and moderate to severe hearing loss24 monthsn = 703
Hearing aids showed no clear effect on NfL in humans (untreated hearing loss without substantial cognitive impairment) (difference: -0.159; 95 %CI: -0.348, 0.029).
“After six months of hearing aid use, we re-evaluated the MMSE and SRT scores and serum biomarkers levels in the ARHL group: we recorded significant improvements both in cognitive and word recognition tests and in biomarker values.”
Hearing aids showed no clear effect on depression in humans (active −5.50 vs. sham - 7.32, ES=0.38).
“No significant differences were found between hearing aid and sham groups on depressive symptoms (HRSD: active −5.50 vs. sham - 7.32, ES=0.38, t=0.75, df=19, p=0.464).”
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry·
Hearing aids showed no clear effect on depression in humans (comorbid MDD and moderate-profound hearing loss) (active -5.50 versus sham -7.32, t = 0.75, df = 19, p = 0.46).
“No significant effect on depression was found (HRSD: active -5.50 versus sham -7.32, t = 0.75, df = 19, p = 0.46).”
Human trialcomorbid MDD and moderate-profound hearing loss12 weeks
Hearing aids showed no clear effect on cognitive impairment in older adults with hearing loss (HR 0·90 [95% CI: 0·61, 1·33]).
“HI was not associated with a reduced hazard of cognitive impairment in analyses of the total cohort (Hazard ratio [HR] 0·90 [95% CI: 0·61, 1·33], p=0·59) or in analyses stratified by the ARIC (HR 0·94 [95% CI: 0·54, 1·64], p=0·83) or de novo cohort (HR 0·89 [95% CI: 0·48, 1·67], p=0·72).”
Human trialin older adults with hearing loss3-yearn = 977
Hearing aids were not clearly linked with cognitive impairment in humans (compared with disabling HL without hearing aids) (OR 0.94, 95% CI 0.83-1.07).
“The odds of cognitive impairment did not differ significantly between all participants with HA use and participants with disabling HL without HAs (OR, 0.94; 95% CI, 0.83-1.07)”
Humanscompared with disabling HL without hearing aidsn = 62,072
Hearing aids decrease GFAP in humans (difference: −0.175; 95% CI: −0.322, −0.028).
“Covariate-adjusted intention-to-treat analyses of three-year change in the primary analytic sample revealed that the hearing intervention was associated with a slower rise in GFAP”
Hearing aids decrease falls in humans (untreated hearing loss and without substantial cognitive impairment) (27% reduction; mean difference: -0.54 [95% CI -0.77 to -0.31]).
“the intervention group had a 27% reduction in the mean number of falls over 3 years compared with the control group”
Human trialuntreated hearing loss and without substantial cognitive impairment3 yearsn = 977
Hearing aids improve hearing Handicap Inventory-Elderly Screening version score in humans (untreated mild-to-moderate hearing loss) (-9.5 points (95% CI: -11.0, -8.0) at Year 3).
“Hearing intervention improved self-reported communicative function compared to a control intervention within 6 months and with effects sustained through 3 years.”
Human trialuntreated mild-to-moderate hearing loss3 years
Hearing aids decrease Hearing Handicap Inventory for the Elderly in humans (active −12.47 vs. sham −4.19, ES=1.05).
“As shown in, after adjusting for age, education and baseline scores, a significant improvement in HHIE was noted for the hearing aid compared to the sham group (active −12.47 vs. sham −4.19, ES=1.05, t=−2.64, df=18, p=0.016).”
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry·
Hearing aids decrease Hearing Handicap Inventory for the Elderly in humans (comorbid MDD and moderate-profound hearing loss) (active -12.47 versus sham -4.19, t = -2.64, df = 18, p = 0.016).
“hearing aids were effective at improving hearing functioning (Hearing Handicap for the Elderly: active -12.47 versus sham -4.19, t = -2.64, df = 18, p = 0.016)”
Human trialcomorbid MDD and moderate-profound hearing loss12 weeksn = 19
Hearing aids improve listening and communication goal achievement in humans (adult-onset mild-to-moderate hearing loss).
“Participant COSI goals, which included categories such as conversation in noise and in quiet or attending church and/or meetings, improved and were not dependent on technology used.”
Human trialadult-onset mild-to-moderate hearing loss~10 weeksn = 459
Hearing aids are linked with a lower risk of dementia in individuals with hearing loss (RD -0.05, 95% CI -0.08, -0.01).
“after 8 years of follow-up, risk of dementia was significantly lower among individuals who initiated hearing aids (risk difference (RD): -0.05, 95% confidence interval (CI): -0.08, -0.01).”
Humansin individuals with hearing loss8 yearsn = 2,314
Hearing aids are associated with ADNC score in humans among participants with documented hearing loss (RR 0.94 per unit increment, 95% CI 0.89–0.99).
“Among 479 participants with documented hearing loss, hearing aid use was associated with lower ADNC level (RR per one unit increment in ADNC score: 0.94; 95% CI: 0.89, 0.99).”
Humansamong participants with documented hearing lossn = 479
Hearing aids are linked with a lower risk of depression in those with moderate to severe HL (aHR 0.65, 95% CI 0.49-0.87).
“Hearing aid use (≥6 h self-reported use per day on average) in those with moderate to severe HL was associated with significantly reduced risk of incident depression (aHR: 0.65; 95% CI, 0.49-0.87, P < .01)”
Humansin those with moderate to severe HL≥6 h per day on average
Hearing aids are associated with dementia diagnosis in humans (People with incident hearing loss; hearing aid users compared with nonusers) (RR 1.43, 95% CI 1.08–1.88).
“HA users exhibited a higher risk of dementia diagnosis than nonusers (risk ratio: 1.43; 95% CI, 1.08-1.88).”
HumansPeople with incident hearing loss; hearing aid users compared with nonusers
Contains public sector information licensed under the Open Government Licence v3.0.
How this record changed
Summary rewritten as its findings changed.
As it read before
Human trials report improved cognition but no dementia effect in people with mild cognitive impairment and moderate-to-severe hearing loss, and lower plasma GFAP but unchanged NfL in hearing loss without substantial cognitive impairment. Four findings span two independent labs; two findings come from papers declaring an interest involving the maker.
A 10-year observational analysis of 2,397 older adults found no clear memory-decline link at high healthcare access among those with uncorrected hearing loss.A 10-year observational analysis of 2,397 older adults found no clear memory-decline link at high healthcare access among those with uncorrected hearing loss.
Compared with the reference group, relative rates of death were 1.19 for mild, 1.55 for moderate and 1.56 for moderately severe or worse hearing loss.Compared with the reference group, relative rates of death were 1.19 for mild, 1.55 for moderate and 1.56 for moderately severe or worse hearing loss.
Over 24 months, dementia conversion was 3.09% with hearing aids compared with 4.74% with hearing care education, a non-significant difference.Over 24 months, dementia conversion was 3.09% with hearing aids compared with 4.74% with hearing care education, a non-significant difference.
Among adults aged 85 and older, model-adjusted probabilities of probable dementia were 60.2% for Hispanic adults and 35.1% for non-Hispanic White adults.Among adults aged 85 and older, model-adjusted probabilities of probable dementia were 60.2% for Hispanic adults and 35.1% for non-Hispanic White adults.